NRXP — NRX Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1719406 ·
Last close
$2.45
Market Cap
$106.07M
52W High
$5.05
52W Low
$1.62
ADV30
1,429,690
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,159,000 | 285,000 | -8,145,000 | -2,175,000 | 27,815,000 | 19,822,000 | 29,801,000 |
| Jun 2026 | 1,101,000 | 426,000 | -6,501,000 | -16,520,000 | 34,160,000 | 26,686,000 | 34,330,000 |
| Mar 2026 | 1,068,000 | 437,000 | -4,748,000 | -1,430,000 | 11,903,000 | 6,713,000 | 25,719,000 |
| Dec 2025 | 983,000 | 575,000 | -4,624,000 | 360,000 | 12,956,000 | 7,797,000 | 28,893,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,774,000
Investing CF
$-3,707,000
Financing CF
$47,257,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.73
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-324,845,000
Inventory
—
Receivables
$206,000
ST Investments
—
EBIT TTM
$-22,336,000
Pretax Income TTM
$-23,480,000
Interest Exp TTM
$1,144,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,394,000
EBITDA
$-19,762,000
Free Cash Flow
$-9,639,625
Enterprise Value
$121,241,768
Total Cash
$26,686,000
Total Debt
$834,000
Shares Out
43,295,767
Trailing EPS
$-0.51
Book Value
$-0.00
ROE
—
ROA
-64.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,225,000 | -16,224,000 | -28,622,000 | 12,956,000 | 28,893,000 | -15,937,000 | -14,112,000 |
| Dec 2024 | 0 | -18,502,000 | -25,126,000 | 3,651,000 | 26,874,000 | -23,223,000 | -10,637,000 |
| Dec 2023 | 0 | -27,587,000 | -30,150,000 | 7,315,000 | 19,048,000 | -11,733,000 | -21,657,000 |
| Dec 2022 | 0 | -44,335,000 | -39,754,000 | 25,816,000 | 18,407,000 | 7,409,000 | -39,755,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$3,396,000
NetIncome TTM
$-23,479,000
OpCashFlow TTM
—
Assets (Latest)
$34,160,000
Forward EPS
$0.50
Max Pain — expiry 2027-06-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.00 · spot: $2.80 · call volume: 4,027 · put volume: 123
Expected Move to 2027-06-17:
±$2.09
(74.64%) —
implied range
$0.71 –
$4.89
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ORGO | Organogenesis Holdings Inc. | $105.35M | $0.81 | — |
| OKUR | OnKure Therapeutics, Inc. | $104.50M | $2.58 | — |
| CATX | Perspective Therapeutics, Inc. | $103.84M | $0.86 | — |
| NERV | Minerva Neurosciences, Inc. | $103.13M | $2.16 | — |
| FHTX | Foghorn Therapeutics Inc. | $109.73M | $1.83 | — |
News headlines (Yahoo Finance, 1h cache)
NRx (NRXP) Q3 2026 Earnings Call Transcript
2026-11-18 15:29 · Yahoo
What NRx Pharmaceuticals (NRXP) Said on Its Q3 Earnings Call
2026-11-17 15:15 · Yahoo
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-17 12:18 · Yahoo
NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue Estimates
2026-11-16 23:00 · Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
2026-11-12 21:01 · Yahoo
NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage
2026-11-11 12:00 · Yahoo
NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection
2026-10-30 14:14 · Yahoo
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
2026-10-30 11:00 · Yahoo
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
2026-10-29 20:00 · Yahoo
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
2026-10-19 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.